Protocols and Documentation Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below
The GLP-1 antagonist Ex-9 reversed the effects of Ex-4 on the expression of ACC and CPT1a
Signs of Dehydration: This includes extreme thirst, dark-colored urine, dizziness upon standing, or a very dry mouth
But, if the company describes its product as an immunity booster, the agencys authority is less clear
The correct classification: Pure GLP-1 agonists: exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, efpeglenatide, orforglipron Dual GIP/GLP-1 agonists: tirzepatide Triple agonists (GIP/GLP-1/glucagon): retatrutide Retatrutide, approved in early 2026, adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism